atai Life Sciences (ATAI)
(Delayed Data from NSDQ)
$1.93 USD
+0.09 (4.89%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.92 -0.01 (-0.52%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for atai Life Sciences NV falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 179 | 273 | 362 | 97 | 30 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 1 | 0 | 1 | 0 | 8 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 14 | 12 | 2 | 1 |
Total Current Assets | 186 | 287 | 375 | 100 | 39 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 0 |
Investments & Advances | 92 | 7 | 28 | 8 | 23 |
Other Non-Current Assets | 11 | 7 | 4 | 2 | 0 |
Deferred Charges | 0 | 0 | 0 | 2 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 7 | 0 | 0 |
Total Assets | 293 | 305 | 414 | 112 | 62 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 2 | 6 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 17 | 15 | 9 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 20 | 20 | 21 | 12 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 3 | 0 | 1 | 2 | 0 |
Long-Term Debt | 15 | 15 | 0 | 0 | 0 |
Non-Current Capital Leases | 1 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 10 | 5 | 7 | 2 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 49 | 40 | 28 | 16 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 19 | 19 | 18 | 13 | 11 |
Capital Surplus | 795 | 774 | 725 | 262 | 70 |
Retained Earnings | -551 | -510 | -358 | -190 | -20 |
Other Equity | -18 | -17 | 1 | 10 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 244 | 266 | 386 | 95 | 60 |
Total Liabilities & Shareholder's Equity | 293 | 305 | 414 | 112 | 62 |
Total Common Equity | 244 | 266 | 386 | 95 | 60 |
Shares Outstanding | 166.00 | 165.80 | 160.30 | NA | NA |
Book Value Per Share | 1.47 | 1.60 | 2.41 | 0.00 | 0.00 |
Fiscal Year End for atai Life Sciences NV falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 179 | 209 | 227 | 250 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 1 | 0 | 9 | 9 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 6 | 7 | 6 | 9 |
Total Current Assets | NA | 186 | 216 | 243 | 268 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 92 | 75 | 4 | 6 |
Other Non-Current Assets | NA | 11 | 12 | 1 | 1 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 3 | 3 | 3 | 3 |
Total Assets | NA | 293 | 308 | 254 | 281 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 6 | 4 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 15 | 13 | 13 | 14 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 1 | 1 | 1 |
Total Current Liabilities | NA | 20 | 20 | 18 | 20 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 3 | 0 | 0 | 0 |
Long-Term Debt | NA | 15 | 15 | 15 | 15 |
Non-Current Capital Leases | NA | 1 | 1 | 1 | 1 |
Other Non-Current Liabilities | NA | 4 | 4 | 4 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 49 | 40 | 38 | 40 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 19 | 19 | 19 | 19 |
Capital Surplus | NA | 795 | 799 | 792 | 783 |
Retained Earnings | NA | -551 | -533 | -577 | -544 |
Other Equity | NA | -18 | -17 | -18 | -17 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 244 | 269 | 216 | 241 |
Total Liabilities & Shareholder's Equity | NA | 293 | 308 | 254 | 281 |
Total Common Equity | 0 | 244 | 269 | 216 | 241 |
Shares Outstanding | 166.00 | 166.00 | 166.00 | 166.00 | 166.00 |
Book Value Per Share | 0.00 | 1.47 | 1.62 | 1.30 | 1.45 |